期刊
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
卷 86, 期 -, 页码 158-167出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2015.07.027
关键词
Proteasome; mTOR; Heart; Rapamycin; Immunoproteasome; Inflammation
资金
- National Natural Science Foundation of China [30900673]
- Wu Jieping Medical Foundation of China [320.6977.1134]
- Natural Science Foundation of Shaanxi Province [SJ08-ZT10]
- Foundation of Health Department of Shaanxi Province [2012D13]
- AFAR (American Federation for Aging Research)
The mammalian target of rapamycin (mTOR) plays an important role in cardiac development and function. Inhibition of mTOR by rapamycin has been shown to attenuate pathological cardiac hypertrophy and improve the function of aging heart, accompanied by an inhibition of the cardiac proteasome activity. The current study aimed to determine the potential mechanism(s) by which mTOR inhibition modulates cardiac proteasome. Inhibition of mTOR by rapamycin was found to reduce primarily the immunoproteasome in both H9c2 cells in vitro and mouse heart in vivo, without significant effect on the constitutive proteasome and protein ubiquitination. Concurrent with the reduction of the immunoproteasome, rapamycin reduced two important inflammatory response pathways, the NF-kappa B and Stat3 signaling. In addition, rapamycin attenuated the induction of the immunoproteasome in H9c2 cells by inflammatory cytokines, including INF gamma and TNF alpha, by suppressing NF-kappa B signaling. These data indicate that rapamycin indirectly modulated immunoproteasome through the suppression of inflammatory response pathways. Lastly, the role of the immunoproteasome during the development of cardiac hypertrophy was investigated. Administration of a specific inhibitor of the immunoproteasome ONX 0914 attenuated isoproterenol-induced cardiac hypertrophy, suggesting that the immunoproteasome may be involved in the development of cardiac hypertrophy and therefore could be a therapeutic target In conclusion, rapamycin inhibits the immunoproteasome through its effect on the inflammatory signaling pathways and the immunoproteasome could be a potential therapeutic target for pathological cardiac hypertrophy. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据